以岭药业创新药参松养心胶囊树立房颤中医药防治新标杆

Core Viewpoint - The newly released guideline recommends the innovative traditional Chinese medicine, Shen Song Yang Xin Capsule, for the management of atrial fibrillation (AF), marking a significant milestone in integrating traditional Chinese medicine into modern cardiovascular treatment [1][2][14]. Group 1: Guideline Development and Significance - The guideline was developed by 67 experts from various medical associations, incorporating recent research and consensus on atrial fibrillation management [1]. - It emphasizes a comprehensive management approach for AF, integrating prevention, acute treatment, and long-term follow-up, highlighting the importance of multidisciplinary collaboration [2][3]. Group 2: Clinical Evidence and Recommendations - Shen Song Yang Xin Capsule is recommended for maintaining sinus rhythm in paroxysmal AF patients and reducing recurrence rates in patients post-radiofrequency ablation [1][4]. - The capsule's efficacy was supported by a multi-center randomized controlled trial involving 349 patients, showing a total effective rate of 62.3%, comparable to the drug Propafenone [5][7]. Group 3: Mechanism and Unique Advantages - The capsule operates through a unique formulation that addresses both rapid and slow heart rhythms, making it particularly suitable for elderly patients who may experience both types of arrhythmias [9][12]. - Its mechanism includes regulating ion channels and autonomic nervous functions, which helps improve cardiac conduction and stabilize heart rates [10][11]. Group 4: Future Implications and Research Directions - The inclusion of Shen Song Yang Xin Capsule in the guideline is expected to enhance the treatment options available for AF, particularly in the context of post-ablation management [14][15]. - Experts advocate for further high-quality clinical research to validate the efficacy of traditional Chinese medicine in treating arrhythmias, aiming for broader acceptance and integration into global treatment protocols [15][16].